INTRODUCTION
Current therapeutic approaches for human breast cancer include hormonal therapy with antiestrogenic compounds, as well as surgery, radiotherapy, hyperthermia, and chemotherapy (Hortobagyi, 1998) . However, conventional strategies for treatment of breast cancer are yet unsatisfactory and limited. Therefore, there is an urgent need to develop more effective therapeutic approaches for prevention and treatment of breast cancer. In recent years, an increasing number of structurally diverse HDAC inhibitors have been identifi ed as a promising new class of potential anticancer agents (Carron et al., 1997; Butler et al., 2000; Brown and Strathdee 2002; Bulavin et al., 2004) . Currently available HDAC inhibitors fall into four structural classes; short chain fatty acids, hydroxamic acids, cyclic tetrapeptides/epoxides, and benzamides (Drummond et al., 2005) . Short chain fatty acids such as phenylbutyrate, phenylacetate, and the antiepileptic drug valproic acid inhibit HDAC activity and affect the expression of numerous genes Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and have a key role in the epigenetic regulation of gene expression. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new class of potential anti-cancer agents. In recent years, a number of structurally diverse HDAC inhibitors have been identifi ed and these HDAC inhibitors induce growth arrest, differentiation and/or apoptosis of cancer cells in vitro and in vivo. However, the underlying molecular mechanisms remain unclear. This study aimed at investigating the anti-tumor activity of various HDAC inhibitors, IN-2001, using T47D human breast cancer cells. Moreover, the possible mechanism by which HDAC inhibitors exhibit anti-tumor activity was also explored. with disparate cellular functions (Saito et al., 1999) . Newer compounds such as cyclic hydroxamic acid containing peptides (CHAP) inhibit nanomolar concentrations and are synthetic hybrids of SAHA and the cyclic peptides Komatsu et al., 2001) . The fungal metabolites trapoxin A, apicidin, and depsipeptide (FR901228) are cyclic tetrapeptides with potent HDAC inhibitory activities. The other class includes the synthetic benzamide derivatives such as MS-275 and CI-994 (Suzuki et al., 1999) . MS-275 is orally bioavailable and exerts antiproliferative effects at micromolar levels against a variety of cancer cell types (Saito et al., 1999; Papeleu et al., 2005) . The result of HDAC inhibition is believed not to have a generalized effect on the genome but rather only effects the transcription of a small subset of the genome. Differential display analysis of transformed lymphoid cell lines revealed that the expression of only 2-5% of transcribed genes is changed signifi cantly after treatment with HDAC inhibitor, TSA (Van et al., 1996) . Recent cDNA microarray studies have shown that treatment with HDAC inhibitors modulates the expression of
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Biomol Ther 20(1), 81-88 (2012) www.biomolther.org http://dx.doi.org/10.4062/biomolther.2012.20.1.081 a selective subset of less that 10% of expressed genes in different cell types, with a near equal proportion of these being induced as repressed (Glaser et al., 2003) . The commonly up-and down-modulated gene transcripts identifi ed in these expression microarray studies, as well as in numerous singlegene expression studies ( Van et al., 1996; Mariadason et al., 2000; Suzuki et al., 1999) , are those encoding known tumorassociated proteins that mediate proliferation and cell cycle progression, survival factors, growth factor receptors, kinase and signaling transduction intermediates, DNA synthesis/ repair enzymes, shuttling proteins, transcription factors, and proteases. p21 WAF1 mediates growth arrest in the G 1 phase of the cell cycle by inhibiting cyclin-dependent kinase complexes that regulate cell cycle progression (Gartel and Tyner, 1998; Blobel, 2000; Biswas et al., 2006) . All known HDAC inhibitors including butyrate Archer et al., 1998) , TSA , depsipeptide, oxamfl atin (Kim et al., 1999) , MS-275 (Saito et al., 1999) , trapoxin (Sambucetti et al., 1999) , and SAHA Gui et al., 2004) , have been known to induce WAF1 transcription. Increased transcription of the p21 WAF1 gene by HDAC inhibitors is associated with an increased level of histone acetylation at the p21 WAF1 gene promoter (Chan et al., 2001; Gui et al., 2004) .
In order to develop a anti-cancer drug candidate, in this study, we tried to evaluate the anti 
MATERIALS AND METHODS

Chemicals
HDAC inhibitors, such as Trichostatin A, IN2001, SAHA, and LAQ were generously provided from Dr. D. K. Kim (EwhaWomans University, Seoul, South Korea). HC toxin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Sodium pyrubate, penicillin-streptomycin, fetal bovine serum (FBS), trypsin-EDTA, minimum essential medium (MEM), and RPMI were acquired from GibcoBRL (Rockville, MD, USA). Antibodies were from Santa Crutz Biotechnology Inc. (Santa Crutz, CA, USA).
Cell lines and cell culture conditions
T47D cells were obtained from Korean Cell Line Bank (KCLB, Seoul, South Korea). T47D cells were maintained in RPMI1640 medium, supplemented with fetal bovine serum and penicillin-streptomycin. Cells were routinely maintained at 37 o C and in 5% CO 2 .
Cell proliferation assay
Cells were plated in 96 well plates at a density of 10 4 cells per well. The following day, the cells were treated with chemicals. The number of cells was measured based on the modifi ed SRB assay. Cells were treated with cold 10% trichloroacetic acid (TCA) and incubated at 4 o C for 30 min, then washed fi ve times with tap water and left to dry. TCA-fi xed cells were stained for 30 min with 0.4% (w/v) sulforhodamineB (SRB) dissolved in 1% acetic acid. Wells were washed with tap water and air dried. Bound dye was solubilized with 10 mM Tris base (pH 10.5) in a shaker for 30 min. Finally, optical intensity was read using ELISA reader (Bio-Rad, Hercules, CA, USA) at 570 nm.
Flow activated cell sorter (FACS) analysis
Cells were plated in 60 mm 2 dishes and exposed to chemicals. Treated cells were detached using trypsin-EDTA and fi xed with 70% ethanol. After centrifugation, the cells were treated with RNase A (10 μg/ml) for 20 min at 37 o C and stained with propidium iodide (2 μg/ml) for 30 min at 37 o C in the dark. The DNA content per cell was evaluated in a FACScalibur (Becton Dickinson, San Diego, CA, USA).
RT-PCR) analysis
Cells were plated in 60 mm 2 dishes and exposed to chemicals for 24 hr. Total RNA was extracted using Trizol reagent (Invitrogen Co., Carlsbad, CA, USA). Reverse transcription was carried out on 3 μg of total RNA diluted in a 22.5 μl mixture containing 1 μl random primer (0.5 μg/ml), 1 μl dNTP (1 mM), 2 μl DTT, 4 μl RT buffer (5X), 1 μl M-MLV reverse transcriptase (200 U/μl), 0.5 μlRNasin (40 U/μl), and H 2 O. After incubation at 37 o C for 1 hr, the reverse transcriptase was inactivated for 10 min at 95 o C and cDNA was stored at −20 o C or immediately used for PCR. 1 μl of the synthesized cDNA was subjected to PCR amplifi cation with special primer in a 10 μl reaction containing dNTP and Taq polymerase. DNA was denatured at 95 o C for 5 min and cycled immediately 25 times at 95 o C for 30 sec with specifi c annealing temperature chosen by preliminary experiments; and extended at 72 o C for 1 min. The PCR reaction ended with 5 min incubation at 72 o C. Special primers (GAPDH; 5'ACATCgCTCAgACACCATgg3'; 5' gTAgTTgAggTCAATgAAggg3': p21;5'gAACTTCgACTTTgTCACCgAg3'; 5' CgTTTTCgACCCTgAgAgTCTC3': Cyclin D1;5'AgCCATggAA CACCAgCTC3';5' gCACCTCCAgCATCCAggT3': Cyclin D2;5' TACTTCAAgTgCgTgCAgAAggAC3';5' TCCCACACTTCCAg TTgCgATCAT3') for PCR amplifi cation and PCR products were analyzed on 2% agarose gels.
Western blot analysis
Cells were plated in 100 mm 2 dishes and then incubated with chemicals for 24 hr. Cells were collected and homogenized in a lysis buffer (Pro-prep protein extraction solution, INtRON; 20 mMTris, 160 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM PMSF, 1 mM NaF, 1 mMdithiothreitol (DTT), 1 mM sodium orthovanadate, pepstatin, leupeptin, and aprotinin) on ice for 10-20 min. Cell lysates were centrifuged at 14,000 g for 5 min at 4 o C, divided into aliquots and stored at −80°C. Lysates containing 30-50 μg of total protein were separated by electrophoresis on 10%-15% SDS-acrylamide gels and then electrophoretically transferred to polyvinylidenedifl uoride (PVDF) transfer membrane (Hybond-P; Amersham) at 200 mV for 2-3 hr. Membranes were blocked with 3% dry milk in PBST (PBS with 0.1% Tween) over night at 4°C and incubated with specifi c fi rst antibodies for 1-2 hr at R.T. After membranes were washed and incubated with second antibodies conjugated to horse radish peroxidase for 2 hr at R.T., membranes were washed and air dried for ECL detection (ECL Plus; Amersham). Membranes were stripped in mild antibody stripping solution (Re-Blot Plus, Chemicon International, Temecular, CA) at R.T. for 30 min, washed in PBST, and reprobed.
RESULTS
IN-2001 causes dose-dependent growth inhibition
To determine the antiproliferative effect of IN-2001 ( T47D cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specifi c primers. GAPDH served as loading control. For quantification, the band intensity of p21 WAF1 was normalized to that of GAPDH and data was expressed as fold induction compared to control group. *Signifi cantly different from control (p<0.05). 
HDAC inhibitors increases
HDAC inhibitor decreases cyclin D1 expression and increases cyclin D2 expression
As well as cdk inhibitors, one of the important cell cycle regulatoryproteins is cyclin. In this study, we examined the effect of HDAC inhibitor on the expressions of D-type cyclin (cyclin D1 and cyclin D2). T47D cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr and then examined for the expression of cyclin D1 and cyclin D2 by RT-PCR analysis. In T47D cells, transcription of cyclin D1 and cyclin D2 was oppositely regulated by HDAC inhibitior. HC toxin and LAQ signifi cantly decreased cyclin D1 transcription to 58% and 17% over control level, respectively. However, cyclin D2 mRNA level was increased by 2.8-fold and 3.7-fold compared to control, respectively. TSA, IN2001, and SAHA did not change the expression of D-type cyclin in T47D cells (Fig. 7) .
In MDA-MB-231 cells, TSA, HC toxin, and LAQ signifi cantly down-regulated cyclin D1 mRNA level but did not change cyclin D2 mRNA level. Cyclin D2 mRNA level was up-regulated by IN2001 and SAHA to 1.6-fold and 1.8-fold, respectively (Fig. 7) .
HDAC inhibitor decreasesthymidylate synthase expression
Thymidylate synthase (TS) is an essential enzyme for DNA replication and repair because it provides the sole intracellular source of dTMP. Thus, it has been a major target of chemotherapeutic agents, such as fl uoropyrimidines (i.e. 5-FU) and antifolates (i.e. TDX, ZD931, and MTA). Therefore, we examined the effect of HDAC inhibitor on the TS gene expression. T47D cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr and then TS mRNA level Fig. 6 . Effect of HDAC inhibitor on the expression of cdk inhibitor. T47D cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Protein extracts were prepared and 50 μg of protein extracts were separated by 12% SDS-PAGE. Blots were probed with the corresponding antibodies. actin served as the loading control. For quantifi cation, the band intensity of p21 WAF1 and p27
KIP1 was normalized to that of actin and data was expressed as fold induction compared to control group. cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specifi c primers. GAPDH served as the loading control. For quantifi cation, the band intensity of cyclin D was normalized to that of GAPDH and data was expressed as fold induction compared to control group. *Signifi cantly different from control (p<0.05). was determined using RT-PCR technique. As shown in Fig.  8 , T47D cells treated with TSA, HC toxin, IN2001, SAHA, and LAQ showed down-regulation of TS mRNA level to 37%, 24%, 45%, 37%, and 15% over control level, respectively.
Eff ect of HDAC inhibitor on the apoptosis
To determine whether anti-proliferative effect of HDAC inhibitor is related with induction of apoptosis, we examined the effect of HDAC inhibitor on the apoptosis. Moreover, we tried to elucidate the underlying mechanism of apoptosis induced by HDAC inhibitors. T47D cells treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for various time period (12 hr, 24 hr, or 48 hr). And then cell were stained with fl uorescent PI dye and then subjected to FACS analysis to measure the sub-G 1 populations, which represent apoptotic cells with less than 2N DNA content. As shown in Fig. 9 , T47D cells showed signifi cant inductin of apoptosis when cells were treated with HDAC inhibitors for more than 24 hr. However, exceptionally, LAQ signifi cantly increased apoptotic sub-G 1 populations with 12 hr treatment (11.44%, compared to 3.30% in control). 24 hr treatment of HDAC inhibitors increased in apoptosis ranging from 12.3% to 20.86% compared to the control value of 6.32%. With 48 hr treatment, more apoptotic cells were detected by HDAC inhibitors. When cells were treated with HDAC inhibitors for 48 hr, 13.8-27.8% of apoptotic cells were observed, whereas untreated control cells showed 7.2% of sub-G 1 peak.
DISCUSSION
HDAC inhibitors have been found to induce cell growth arrest, differentiation, and/or apoptosis, and exhibit potent antimetastatic, antiangiogenic, and immuno-modulatory properties in a variety of transformed cells in vitro and in vivo that can contribute to the inhibition of tumour development and progression (Zhou et al., 2000; Marks et al., 2001; Wittich et al., 2002; Johnstone and Licht, 2003; Yang, 2004) .
HDAC inhibitors may achieve their antitumor effects through reactivation of dormant tumor suppressor genes (Vrana et al., 1999; Wade, 2001; Villar-Garea and Esteller, 2004) . In cancer, some genes are transcriptionally silenced by the inappropriated recruitment of HDACs, e.g., tumor suppressor genes (Glaser et al., 2003) . Known repressors are multiproteins that contain DNA binding proteins (e.g., NcoR, SMRT, MEF, MeCP2, and sin3A) that commonly use HDACs to repress transcription and block the function of the tumor suppressor gene. The arche-typical gene silenced in this manner in human cancer is the cyclin-dependent kinase inhibitor p21
WAF1
. Epigenetic reactivation of p21 WAF1 by HDAC inhibitors has been reported in cancer cell lines (Archer et al., 1998) , and the restoration of p21 WAF1 gene expression by HDAC inhibitors is associated with enrichment of hyperacetylated histones at the p21 WAF1 promoter (Bereshchenko et al., 2002; Gui et al., 2004) . Demethylatingagents such as 5-aza-2'-deoxycytidine are particularly interesting owing to the interaction of DNA methylation with histone deacetylation in gene silencing of tumor suppressor genes. Combinations of 5-aza-2'-deoxycytidine with HDAC inhibitors, TSA or depsipeptide, were shown to reactivate silenced tumor suppressor genes including MLH1, TIMP3, CDKN2B, CD-KN2A, ARHI, gelsolin, and maspin, synergistically increasing the level of tumor cell apoptosis (Drummond et al., 2005) . In addition to stand alone-therapeutics for chemotherapy, HDAC inhibitors seem to be suitable for combination therapy as "sensitizer drugs", enhancing the antitumor effects of specifi c chemotherapeutics. In fact, a proportion of the clinical trials using Fig. 8 . Effect of HDAC inhibitor on the thymidylate synthase expression. T47D cells were treated with vehicle (0.1% DMSO) or 1 μM HDAC inhibitors for 24 hr. Total RNA was isolated and then subjected to RT-PCR using specific primers for thymidylate synthase. GAPDH served as the loading control. For quantification, the band intensity of TS was normalized to that of GAPDH and data was expressed as fold induction compared to control group. *Signifi cantly different from control (p<0.05).
www.biomolther.org HDAC inhibitors involve a combination of an established antitumor compound together with a HDAC inhibitor (Villar-Garea and Esteller, et al.,2004) . The drug combinations may have 2 advantages: fi rst, the dose of each substance necessary for cell growth inhibition or apoptosis is usually much lower than if used separately, reducing side effects and toxicity, and second, resistance to certain chemicals can be overcome in some cases by combining drugs. For instance, cell death after treatment with etoposide, comptothecin, and other substances that cross-link DNA and Topo II enzymes increases if the cell lines are pretreated with either TSA and SAHA, probably because the chromatin changes caused by the hydroxamic acids facilitate cross-linker access to the target (Kim et al.,2003) . Combinations of nuclear receptor ligands, such as all trans retinoic acid (ATRA), or vitamin D analaogs, such as 1,25-dihydroxyvitamin D, with HDAC inhibitors have been shown to increase differentiation and apoptosis in cancer cells and also inhibit tumor growth in vivo (Banwell et al.,2003; Drummond et al., 2005; Joung et al., 2006) .
